Urinary Tract Infection (UTI) Treatment to Grow by USD 2.66 Bn | Rising Use of Urinary Catheters to Drive Growth | Technavio

The urinary tract infection (UTI) treatment market size is expected to grow by USD 2.66 bn from 2020 to 2025. The market's growth momentum is going to accelerate at a CAGR of 4.71% during this period. The market is expected to record a year-over-year growth rate of 3.97% in 2021.

Key Vendor Offerings:

The offerings of some of the key vendors are mentioned below:

• Abbott Laboratories: The company offers Abocran for UTI treatment purposes.
• AbbVie Inc.: The company offers different types of UTI treatment products under the brand name Monurol (fosfomycin tromethamine) oral granules.
• AstraZeneca Plc: The company offers an antibiotic medicine CAZ-AVI for complicated UTI treatment purposes.
• Boehringer Ingelheim International GmbH: The company offers different types of UTI treatment products under the brand name FLOMAX.
• Cipla Inc.: The company offers different types of capsules for UTI treatment under the brand name URIFAST Capsules.

Regional Analysis

• 35% of the growth will originate from North America.
• The US and Canada are the key countries for the urinary tract infection (UTI) treatment market in North America.
• Market growth in this region will be slower when compared to other regions.

For additional highlights of the contribution of each region, View Our Free Sample 

Notes:

• The urinary tract infection (UTI) treatment market size is expected to accelerate at a CAGR of 4.71% during the forecast period.
• The urinary tract infection (UTI) treatment market is segmented by type (uncomplicated UTI and complicated UTI) and geography (North America, Europe, Asia, and ROW).
• The market is fragmented due to the presence of many vendors holding significant market share.
• The research report offers information on several market vendors, including Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., and SHIONOGI Co. Ltd.

Subscribe to Technavio's "Lite Plan" billed annually at USD 3000 that enables you to download 3 reports a year and view 3 reports every month.

Related Reports:

• Female Infertility Drugs Market: The female infertility drugs market has been segmented by route of administration (parenteral, oral, and vaginal) and geography (North America, Europe, Asia, and ROW). Download Free Sample Report      
• Cancer Immunotherapy Market: The cancer immunotherapy market has been segmented by type (monoclonal antibodies, cancer vaccines, and check point inhibitors and immunomodulators) and geography (North America, Europe, Asia, and ROW). Download Free Sample Report

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio